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a b s t r a c t
Three isolates of Streptococcus agalactiae, recovered from residents of the metropolitan area
of Rio de Janeiro with signiﬁcant bacteriuria, were found to be resistant to levoﬂoxacin.
Determination of the minimal inhibitory concentration (MIC) conﬁrmed one isolate as inter-
mediate and two as resistant to levoﬂoxacin. No reduction in levoﬂoxacin MIC was observed
with reserpine, indicating that resistance was not caused by an efﬂux mechanism. Typi-
cal point mutations were observed in the quinolone resistance determinant region of gyrA
and parC. Other point mutations in parC generated novel altered codons: Ser80→Pro in the
intermediate resistance isolate, and Gly128→Asp in a resistant isolate. Through molecular
modeling, it was possible to observe that these novel substitutions might not play a role in
resistance, since these amino acids were not involved in the antibiotic binding site. Pulsedﬁeld gel electrophoresis proﬁles revealed a non-clonal trend among these isolates. This is
the ﬁrst report of genetic characterization of levoﬂoxacin-resistant S. agalactiae strains in
Brazil.
Ala or Tyr). Such substitutions, in most cases, decrease the
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDStreptococcus agalactiae (group B Streptococcus, GBS) is one of
the most important agents of infectious diseases in new-
borns, causing life-threatening diseases such as meningitis
and septicemia.1 GBS is also responsible for infections in non-
pregnant individuals, especially elderly and thosewith certain
underlying conditions.2
Penicillin remains the ﬁrst choice to treat GBS infections,
although strains with reduced susceptibility to this antimi-
3crobial agent have been recently described. Conversely, GBS
resistance to alternative therapy, such as macrolides and lin-
cosamides, has emerged in the last decades. Fluoroquinolone
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Este é um artigo Open Access sob a licençaresistance in Streptococcus agalactiae was ﬁrst described in
Japan in 2003,4 and after that, resistant isolates were also
recovered in other countries, although as rare events.5–8 The
majormechanismof ﬂuoroquinolone resistance amongGBS is
related to point mutations in the quinolone resistance deter-
minant region (QRDR) of gyrA, leading to amino acid substitut-
ions (Ser-81→Leu; Glu-85→Ala or Lys) and parC (Ser-79→ Phe,
4,5uminense, Rua Hernani de Melo 101, Niterói, RJ, 24210-130, Brazil.
afﬁnity of the antibiotic with the enzyme, because the change
in amino acid hampers the interactions of the antibiotic
in the binding site. Active efﬂux has been addressed as a
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Table 1 – Antimicrobial susceptibility testing and pulsed ﬁeld gel electrophoresis (PFGE) patterns of group B Streptococcus
(GBS) isolates.
Isolate Date of recovery Levoﬂoxacin susceptibility testing Other antimicrobials susceptibility testingb PFGE
pattern
Disk diffusion MIC determination (mg/L)a Cli Ery Pen Tet Van
Agar dilution Epsilometric
CF21 Aug/07 R 32 > 32 S S S S S A
CF113 Jun/08 S 1 1 S S S R S B
CR221 Apr/08 R 16 > 32 S S S R S C
CR450 May/10 R 4 4 S S S R S B1












































oLaboratory Standards Institute, were: susceptible (S) ≤ 2mg/L; inter
b Susceptibility testing by disk diffusion method. Cli, clindamycin; Er
uoroquinolone resistance mechanism in Streptococcus
neumoniae,9 but has never been described in S. agalactiae.5,6
During a recent antimicrobial susceptibility survey con-
ucted in Rio de Janeiro by this group, Nakamura et al.10 found
ne clinical GBS isolate resistant to ﬂuoroquinolones, but no
enetic characterizationwas performed in this previous study.
ere, the phenotypic and genetic characteristics of three
evoﬂoxacin non-susceptible GBS isolates circulating in this
eographical area are described.GBS isolates (n=500), identi-
ed by phenotypic tests (beta-hemolytic Gram-positive cocci,
atalase negative, CAMP factor positive, hippurate hydrol-
sis test positive, streptococcal serological test positive to
roup B)11 were recovered from several specimens for rou-
ine diagnosis in two clinical laboratories (Instituto Fernandes
igueira and Fleury Group, Rio de Janeiro) from 2007 to 2010.
ll isolates were submitted to susceptibility testing to rec-
mmended antimicrobial agents by disk diffusion method.12
hree epidemiologically unrelated isolates of GBS, suscepti-
le to clindamycin, erythromycin, penicillin, and vancomycin,
ere found to be resistant to levoﬂoxacin (Table 1). These
solates were recovered from the urine of patients with sig-
iﬁcant bacteriuria (> 105 CFU/mL). One isolate (CF21) was
ecovered in 2007 from a hospitalized 15-year-old female
reviously submitted to renal surgery. Two isolates were
ecovered from outpatients, a 66-year-old female in 2008
CR221), and a 56-year-old male in 2010 (CR450). This latter
atient had used norﬂoxacin prior to the GBS positive cul-
ure. A levoﬂoxacin susceptible isolate (CF113) was included
or comparison. This isolate was recovered from a 19-year-old
regnant patient with signiﬁcant bacteriuria. Determination
f levoﬂoxacin minimal inhibitory concentration (MIC) by agar
ilution13 and epsilometric methods (MIC Evalutator, Oxoid
Basingstoke, UK) conﬁrmed two isolates as resistant and
ne as intermediate. Such discrepancy when using different
ntimicrobial susceptibility test methodologies was previ-
usly reported inGBS isolates.14 No change in levoﬂoxacinMIC
alues was observed when reserpine (70mg/L) was incorpo-
ated in the medium, suggesting that the active efﬂux pump
ystem was not involved in ﬂuoroquinolone resistance. Con-
inuous GBS antimicrobial susceptibility surveys conducted
n the last years allowed the detection of three (0.6%) non-
usceptible levoﬂoxacin strains, recovered from residents
f the metropolitan area of Rio de Janeiro with signiﬁcantate resistance (I) = 4mg/L; resistant (R) ≥ 8mg/L.
thromycin; Pen, penicillin; Tet, tetracycline; Van, vancomycin.
bacteriuria. In other studies, levoﬂoxacin resistance has been
reported at a frequency of 1%of GBS isolates,mainly recovered
from respiratory and urinary tract specimens.4–7
Ampliﬁcation and sequencing of internal regions of gyrA
and parC genes were performed as described elsewhere.15
Sequences were deposited in the GenBank database and
accession numbers for gyrA and parC were HQ687739 to
HQ687746. Analysis of deduced amino acids sequences was
performed using the software CLC Sequence Viewer (CLC
BioA/S). Point mutations were detected in internal regions of
both gyrA and parC genes. Resistant and intermediate isolates
had Ser-81→Leu in gyrA. In parC, Ser-79→Phe was observed in
both resistant isolates, whereas the intermediate isolate had
another substitution (Ser-80→Pro). An additional substitution
in parC (Gly-128→Asp) was observed in one resistant isolate
(CR221).
In order to check whether the substitution Ser-80→Pro
had an effect in MIC increase, molecular interaction between
levoﬂoxacin and topoisomerase IV was simulated. The pro-
tein topoisomerase IV complexed with levoﬂoxacin was taken
from the Protein Data Bank (PDB) under the code 3K9F with
resolution of 2.90 A˚.16 The complex was visualized using the
program Molegro Molecular Viewer 2.2.0 (Molegro ApS). It was
observed that the hydroxyl group of the amino acid residue
Ser79 interacted through a strong hydrogen bond with the
carboxylic acid group of levoﬂoxacin molecule at a distance
of 3.18 A˚, while the distance of interaction between the drug
and Ser80 residue was 5.80 A˚, what did not feature a hydrogen
bond. This probably indicates that thismutation (Ser-80→Pro),
which is new in GBS, is not implicated in the resistance mech-
anism. Also, Ser-80→Pro has been observed in levoﬂoxacin
susceptible isolates of Streptococcus pyogenes.17 Therefore, the
cause of the intermediate levoﬂoxacin isolate might be the
gyrA mutation, since a MIC increase can be explained by
mutation in either gyrA or parC.6 An additional substitution
(Gly-128→Asp) was observed in one resistant isolate (CR221).
It was observed that the residue Gly128 was located far from
levoﬂoxacin (c.a.26.5 A˚), and thus, there was no possible inter-
action between drug and amino acid.
DNApolymorphismproﬁles of levoﬂoxacin susceptible and
non-susceptible isolates were obtained after digestion with
SmaI and separation of the fragments by pulsed ﬁeld gel elec-
trophoresis (PFGE), as previously described.18 DNA proﬁles
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were compared by visual inspection and the genetic related-
ness was determined according to Tenover et al.19 Analysis
of restriction proﬁles revealed a non clonal trend among
levoﬂoxacin non-susceptible isolates. However, related pro-
ﬁles (two fragment differences) were observed between the
susceptible and the intermediate isolates, suggesting that
despite the lack of epidemiological link among them, they
may have a close genetic relation. Conversely, the patient
whose intermediate resistance GBS isolate was recovered had
recently usednorﬂoxacin,which couldhave contributed to the
selection and spread of isolates that showed an increase in
levoﬂoxacin MIC but remained closely related to the suscepti-
ble isolate. While some studies observed distinct PFGE proﬁles
amongﬂuoroquinolone resistant isolates,5,7 Murayamaet al.15
demonstrated a high level of similarity among them.Also, Fac-
cone et al.8 observed two clones among nine resistant isolates
from Argentina. These results suggest that ﬂuoroquinolone
resistance in GBS may be related to the spread of some clones
or to genetically distinct strains.
Characterization of ﬂuoroquinolone resistant GBS circu-
lating in Rio de Janeiro allowed the conclusion that point
mutations in QRDR are the major resistance mechanism, and
they may occur in a non-clonal trend. Although low levels
of resistance have been observed worldwide, a clinical con-
cern is the high frequency of the use of ﬂuoroquinolones to
treat UTIs, which may contribute to select resistant strains,
especially considering GBS as a frequent uropathogen.
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